

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (canceled).

Claim 2 (currently amended): An antibody or binding fragment thereof which ~~specifically~~ binds MCP-1 receptor polypeptide, wherein the polypeptide ~~is selected from the group consisting of:~~

- ~~(a) a polypeptide comprising~~ comprises the amino acid sequence ~~of SEQ ID NO: 2;~~
- ~~(b) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4; and~~
- ~~(c) a polypeptide encoded by an isolated nucleic acid selected from the group consisting of:~~

- ~~(i) DNA comprising residues 40 through 1161 of the DNA sequence of SEQ ID NO:1~~

- ~~(ii) DNA comprising residues 81 through 1160 of the DNA sequence of SEQ ID NO:3; and~~

- ~~(iii) DNA that, due to the degeneracy of the genetic code, encodes a polypeptide, encoded by any of the foregoing DNA sequences.~~

Claims 3-8 (canceled).

Claim 9 (currently amended): The antibody of claim ~~[[3]]~~ 2, wherein the antibody is labeled with a detectable label.

Claim 10 (currently amended): The antibody of claim ~~[[6]]~~ 9, wherein the detectable label is a radioactive isotope.

Claim 11 (currently amended): The antibody of claim ~~[[3]]~~ 2, wherein the antibody is a monoclonal antibody.

Claim 12 (currently amended): The antibody of claim ~~[[3]]~~ 2, wherein the antibody is a humanized antibody.

Claim 13 (currently amended): A cell line producing the monoclonal antibody of claim ~~[[8]]~~ 11.

Claim 14 (currently amended): The cell line of claim ~~[[10]]~~ 13 that is a ~~eucaryotic~~ eukaryotic cell line.

Claim 15 (currently amended): The cell line of claim ~~[[10]]~~ 13 that is a ~~procaryotic~~ prokaryotic cell line.

Claim 16 (currently amended): A method of making ~~the antibody of claim 3~~ an antibody that binds MCP-1 receptor polypeptide comprising:

(a) immunizing an animal with the polypeptide ~~of claim 3 under conditions to elicit an antibody response~~ comprising SEQ ID NO: 4;

(b) isolating antibody-producing cells from the animal;

(c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;

Appl. No. 09/625,573
Amdt. dated September 26, 2003
Reply to Office Action of June 30, 2003

PATENT

(d) culturing the hybridoma cells; and

(e) isolating from the culture monoclonal antibodies which ~~specifically~~ bind to the ~~polypeptide of claim 3~~ MCP-1 receptor polypeptide.

Claim 17 (currently amended): A composition comprising an antibody according to claim ~~[[3]]~~ 2, and a pharmaceutically acceptable carrier.

Claim 18 (canceled).

Claim 19 (currently amended): The antibody of claim ~~[[3]]~~ 2, wherein the ~~specific~~ binding of the antibody or the binding fragment to the MCP-1 receptor polypeptide results in neutralization of activity of the MCP-1 polypeptide.

Claim 20 (new): An antibody made by the method of claim 16.